Abstract 44P
Background
Circulating tumor cells (CTC) detection has proven to be an important parameter for predicting progression-free and overall survival. CTCs provide a so-called real-time liquid biopsy which gives better opportunities for selection of treatment.
Methods
A prospective observational study conducted the Rajiv Gandhi Cancer Institute & Research Centre, New Delhi. 36 treatment naïve patients of metastatic breast cancer were enrolled from April 2016 and May 2018. CTCs were detected using Cellsearch system. Correlation of CTCs with patient’s outcome after chemotherapy in terms of progression-free survival (PFS) and overall survival (OS) were calculated at one year. The level of CTCs in peripheral blood was measured at baseline before chemotherapy and then at 1 month and 6 months of treatment. All patients underwent PET-CT scan at 3 months and 6 months of treatment.
Results
36 patients were included in this study. The mean CTCs at baseline was 13.8 (0-48), with 75% of patients having CTC ≥5. A positive correlation with the number of sites of metastasis with the number of CTCs was noted (p < 0.001 and R = 0.886). Around 11% of the patients had a complete response (CR) after 3 months of therapy as determined by imaging with a mean number of CTCs 21 (median 17) before starting the treatment and 4.25 (median 4.5) at 1 month (P = 0.14). Similarly, partial response at 3 months, the mean CTCs significantly decreased to 6.3 from 12.9 (p = 0.001). Patients with baseline CTCs<5 had a mean PFS of 9.8 months (95% CI of 7.2 to 12.3) and patients with baseline CTCs ≥5 had a mean PFS of 8.6 months (95% CI of 7.1 to 10.1) (p = 0.37). Patients with CTCs < 5 after one month of treatment had a mean OS of 11.6 months (95% CI of 10.8 to 12.4) and patients with CTCs≥5 after one of treatment had a mean overall survival of 9.6 months (95% CI of 8.0 to 11.2) (p = 0.08).
Conclusions
Our results have implications for both standard care and clinical research in developing countries. More accurate determination of treatment effectiveness early in the course of therapy might spare patient therapy-related toxicity from futile therapy, patient families from financial toxicity and allow treatment to be changed to a more effective regimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi.
Funding
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract